Cobas HCV assay receives CE mark approval in the EU for hepatitis C- Roche
Roche announced the commercial availability of the cobas HCV assay for hepatitis C in countries accepting the CE mark. These new molecular diagnostic assays increase the available menu on the cobas 4800 System.
The cobas HCV test employs Roche’s dual-probe approach to provide an extra layer of protection against mutations that can occur in the viral genome and is designed to accurately detect and quantify hepatitis C virus (HCV) ribonucleic acid (RNA) with state-of-the-art sensitivity in order to confirm active HCV infection or assess a patient’s response to antiviral therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.